, Singapore

Daily Markets Briefing: STI down 2%

Don’t expect any gains today.

The Straits Times Index (STI) ended 69.98 points or 2% lower to 3421.39, taking the year-to-date performance to +0.54%.

The top active stocks today were Singtel, which declined 1.74%, DBS, which declined 2.56%, OCBC Bank, which declined 2.94%, UOB, which declined 2.70% and Venture, with a 3.56% fall.

The FTSE ST Mid Cap Index declined 1.27%, whilst the FTSE ST Small Cap Index declined 1.43%.

OCBC Investment Research noted that US stocks retreated for a second day, whilst the dollar rallied as investors assessed data on jobs and service industries for clues to the timing of interest-rate increases.

Nine industries of the S&P 500 closed down, with Telecommunication Services (-1.12%) leading the laggards whilst Health Care (0.40%) gained.

“The continued correction on Wall Street overnight is likely to weigh further on local sentiments this morning,” OCBC said.

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
Shipping & Marine
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare